Medtronic (NYSE:MDT) EVP Sells $336,963.16 in Stock

Medtronic PLC (NYSE:MDT) EVP Harry Skip Kiil sold 4,189 shares of the firm’s stock in a transaction dated Monday, June 8th. The shares were sold at an average price of $80.44, for a total transaction of $336,963.16. Following the transaction, the executive vice president directly owned 37,227 shares in the company, valued at $2,994,539.88. The trade was a 10.11% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Medtronic Stock Up 1.5%

Shares of MDT traded up $1.24 during trading hours on Tuesday, reaching $81.93. 9,686,764 shares of the stock traded hands, compared to its average volume of 9,318,561. The company has a current ratio of 2.54, a quick ratio of 1.87 and a debt-to-equity ratio of 0.57. The stock has a fifty day simple moving average of $81.31 and a 200 day simple moving average of $91.87. Medtronic PLC has a 52 week low of $73.31 and a 52 week high of $106.33. The company has a market cap of $105.19 billion, a price-to-earnings ratio of 21.96, a PEG ratio of 1.99 and a beta of 0.58.

Medtronic (NYSE:MDT) last released its quarterly earnings results on Wednesday, June 3rd. The medical technology company reported $1.55 earnings per share for the quarter, beating analysts’ consensus estimates of $1.54 by $0.01. Medtronic had a net margin of 13.20% and a return on equity of 14.61%. The company had revenue of $9.81 billion for the quarter, compared to analyst estimates of $9.62 billion. During the same period last year, the firm earned $1.62 earnings per share. The firm’s revenue was up 9.9% on a year-over-year basis. Medtronic has set its FY 2027 guidance at 5.900-6.000 EPS. On average, equities analysts forecast that Medtronic PLC will post 5.94 EPS for the current year.

Medtronic Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 17th. Shareholders of record on Friday, June 26th will be given a $0.72 dividend. This is a positive change from Medtronic’s previous quarterly dividend of $0.71. This represents a $2.88 annualized dividend and a yield of 3.5%. The ex-dividend date of this dividend is Friday, June 26th. Medtronic’s payout ratio is presently 77.21%.

Wall Street Analysts Forecast Growth

Several analysts have commented on the stock. JPMorgan Chase & Co. lowered their price objective on shares of Medtronic from $100.00 to $86.00 and set a “neutral” rating on the stock in a research report on Thursday, June 4th. Truist Financial lowered their price objective on shares of Medtronic from $95.00 to $86.00 and set a “hold” rating on the stock in a research report on Thursday, June 4th. Argus lowered their price objective on shares of Medtronic from $125.00 to $115.00 and set a “buy” rating on the stock in a research report on Monday, April 6th. BTIG Research raised shares of Medtronic from a “neutral” rating to a “buy” rating and set a $90.00 price objective on the stock in a research report on Wednesday, June 3rd. Finally, UBS Group lowered their price objective on shares of Medtronic from $90.00 to $85.00 and set a “neutral” rating on the stock in a research report on Thursday, June 4th. Seventeen investment analysts have rated the stock with a Buy rating and eleven have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $99.00.

More Medtronic News

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic earned a CE mark for its Stealth AXiS robot platform in ENT surgery, which should expand the system’s use across Europe and support adoption of its advanced surgical navigation business. Medtronic earns CE mark for Stealth AXiS robot platform in ENT surgery
• Positive Sentiment: The company received FDA clearance for an updated Nellcor pulse oximetry system with Nell-EQ technology, a product designed to improve reliability and accuracy across diverse patient populations and clinical settings. Medtronic gets FDA nod for updated pulse oximetry system
• Positive Sentiment: Medtronic’s acquisition of SPR Therapeutics was highlighted as a move to strengthen its chronic pain and intervention portfolio, potentially broadening future revenue opportunities. Medtronic plc (MDT) Acquires SPR Therapeutics to Enhance Pain Intervention Prospects
• Neutral Sentiment: Several recent articles argued that Medtronic may be undervalued or a “best buy” in healthcare, which could support investor sentiment, but these pieces are opinion-driven rather than new company announcements. Why Medtronic Stock May Have Just Become the Best Buy in the Entire Healthcare Sector
• Neutral Sentiment: Coverage on Medtronic’s recent share-price rebound and valuation suggests investors are reassessing the stock after a strong short-term move, but this is more of a market commentary than a direct catalyst. Is It Time To Reassess Medtronic (MDT) After Its Recent Share Price Rebound?

Hedge Funds Weigh In On Medtronic

Large investors have recently modified their holdings of the business. Monetary Solutions Ltd purchased a new position in shares of Medtronic in the fourth quarter worth about $27,000. Lodestone Wealth Management LLC purchased a new position in shares of Medtronic in the fourth quarter worth about $27,000. Anfield Capital Management LLC increased its stake in shares of Medtronic by 410.7% in the fourth quarter. Anfield Capital Management LLC now owns 286 shares of the medical technology company’s stock worth $27,000 after purchasing an additional 230 shares in the last quarter. Board of the Pension Protection Fund purchased a new position in shares of Medtronic in the fourth quarter worth about $29,000. Finally, GoalVest Advisory LLC purchased a new position in shares of Medtronic in the fourth quarter worth about $29,000. Hedge funds and other institutional investors own 82.06% of the company’s stock.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).